Sam’s personal motto is ‘to always be in the service of others’ and is energised about making a real difference for patients and their families and to help end brain cancer as a terminal illness.

For the last 10 years Sam has held several senior strategic positions with Cotton On Group and is also Executive Director of Carrie Bickmore’s Carrie’s Beanies 4 Brain Cancer Foundation.

Victorian researchers have made a global breakthrough, uncovering unprecedented insights into how a new drug can slow the growth of low-grade gliomas (LGG) — a type of brain cancer that mostly affects young adults.

This is the first-ever clinical trial run through the BrainPOP (Brain Perioperative Platform), led by The Brain Cancer Centre and backed by a $16 million investment from the Victorian Government.

Low-grade gliomas are a slow-growing but devastating type of brain cancer that significantly impacts the lives of patients, many of whom are young adults in their prime. Characterised by a specific mutation gene called IDH, current treatments are limited and LGG have long been considered incurable.

Thanks to the pioneering BrainPOP clinical trial program, led by The Brain Cancer Centre, this innovative approach involves collecting tumour samples before and after treatment, enabling researchers to learn exactly how therapies work within the brain.

They have been able to directly study how a new drug, Safusidenib, works inside the brain. This oral therapy targets the IDH1 gene mutation found in many LGGs.

https://mail.google.com/mail/u/0/#search/Sam+McGuane/FMfcgzQcpTJzjvnqkvhLXkgFKZxCTbCP

https://www.carriesbeanies4braincancer.com/our-story

The post Saturday, 6th, September, 2025: Sam McGuane CEO – The Brain Cancer Centre-Partnership with breakthrough Carrie’s Beanies 4 Brain Cancer appeared first on Saturday Magazine.